Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

AIMS Experimental data point towards a favourable effect of low serum concentrations of complement mannose-binding lectin (MBL) on myocardial ischaemia/reperfusion (I/R) injury. As comparable data on the role of MBL in human I/R injury is lacking, we investigated the influence of low serum MBL concentrations on mortality of patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS AND RESULTS Mannose-binding lectin was determined in 890 acute STEMI patients that were prospectively recruited in the APEX-AMI trial. This trial had a primary endpoint of death through Day 30 and secondary endpoints of death through Day 90 and the composite of death, cardiogenic shock, or congestive heart failure (CHF) through Days 30 and 90. Samples were taken immediately before PCI and the analysis of MBL limited to patients having received placebo. Patients with serum MBL levels of or below 100 ng/mL were considered to be functionally deficient. Of the 890 patients, 127 had functional MBL deficiency (14.3%). Characteristics of patients with MBL deficiency and those with MBL levels >100 ng/mL did not differ. In patients with MBL deficiency, there was 1 death (0.79%) compared with 42 deaths (5.51%) in patients with MBL levels >100 ng/mL (P = 0.0233) representing an absolute and relative lower mortality in MBL deficient patients of 4.7 and 85%, respectively. Functional MBL deficiency, however, was not associated with decreased risk of the combined endpoints of death and shock or death, shock, and CHF, respectively. CONCLUSION Functional deficiency of complement MBL is associated with reduced mortality in patients with STEMI undergoing PCI. This unique finding suggests that a component of the innate immune system affects mortality in STEMI patients undergoing primary PCI. TRIAL REGISTRATION clinicaltrials.gov, Identifier: NCT00091637.

[1]  I. van der Made,et al.  Macrophage-Specific Expression of Mannose-Binding Lectin Controls Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2009, Circulation.

[2]  Pierre Croisille,et al.  Effect of cyclosporine on reperfusion injury in acute myocardial infarction. , 2008, The New England journal of medicine.

[3]  P. Doevendans,et al.  Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. , 2008, Current pharmaceutical design.

[4]  Ajai Kumar Jain,et al.  PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .

[5]  P. Garred,et al.  Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[6]  T. Woodruff,et al.  Complement mediators in ischemia-reperfusion injury. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[7]  Rodney K. Chan,et al.  The Differing Roles of the Classical and Mannose-Binding Lectin Complement Pathways in the Events following Skeletal Muscle Ischemia-Reperfusion1 , 2006, The Journal of Immunology.

[8]  S. Heatley,et al.  Low mannose-binding lectin function is associated with sepsis in adult patients. , 2006, FEMS immunology and medical microbiology.

[9]  S. Thiel,et al.  Clinical manifestations of mannan-binding lectin deficiency , 2005, Molecular Immunology.

[10]  L. Entz,et al.  High rate of early restenosis after carotid eversion endarterectomy in homozygous carriers of the normal mannose-binding lectin genotype. , 2006, Stroke.

[11]  S. Solomon,et al.  Mannose-Binding Lectin Is a Regulator of Inflammation That Accompanies Myocardial Ischemia and Reperfusion Injury1 , 2005, The Journal of Immunology.

[12]  J. D. de Fijter,et al.  Association Between Mannose‐Binding Lectin Levels and Graft Survival in Kidney Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  W. Reenstra,et al.  Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q 1 , 2005, The Journal of Immunology.

[14]  L. Entz,et al.  High Rate of Early Restenosis After Carotid Eversion Endarterectomy in Homozygous Carriers of the Normal Mannose-Binding Lectin Genotype , 2005 .

[15]  S. Thiel,et al.  Mannan‐Binding Lectin Recognizes Structures on Ischaemic Reperfused Mouse Kidneys and is Implicated in Tissue Injury , 2005, Scandinavian journal of immunology.

[16]  C. Vrints,et al.  Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. , 2005, International journal of cardiology.

[17]  P. Armstrong,et al.  Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. , 2005, American heart journal.

[18]  Vilmundur Gudnason,et al.  Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk , 2005, The Journal of experimental medicine.

[19]  W. Buurman,et al.  The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. , 2004, The American journal of pathology.

[20]  P. Garred,et al.  Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. , 2004, The New England journal of medicine.

[21]  Morten Dahl,et al.  A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency , 2004, The Journal of experimental medicine.

[22]  P. Ward,et al.  Complement in ischemia reperfusion injury. , 2003, The American journal of pathology.

[23]  K. Welsh,et al.  MBL genotype and risk of invasive pneumococcal disease: a case-control study , 2002, The Lancet.

[24]  Salim Yusuf,et al.  The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. , 2002, Journal of the American College of Cardiology.

[25]  S. Thiel,et al.  An assay for the mannan-binding lectin pathway of complement activation. , 2001, Journal of immunological methods.

[26]  Michael C. Montalto,et al.  Inhibition of Mannose-Binding Lectin Reduces Postischemic Myocardial Reperfusion Injury , 2001, Circulation.

[27]  S. Thiel,et al.  Association between deficiency of mannose-binding lectin and severe infections after chemotherapy , 2001, The Lancet.

[28]  M. Melbye,et al.  Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. , 2001, JAMA.

[29]  S. Thiel,et al.  Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. , 2000, Journal of immunological methods.

[30]  V. Videm,et al.  Association of mannose-binding-lectin deficiency with severe atherosclerosis , 1998, The Lancet.

[31]  D. Coggon,et al.  Prospective cohort study of predictors of incident low back pain in nurses , 1997, BMJ.

[32]  A. Svejgaard,et al.  Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency , 1995, The Lancet.

[33]  R. Bolli,et al.  Reperfusion-induced injury manifestations, mechanisms, and clinical relevance. , 1991, Trends in cardiovascular medicine.

[34]  S. Thiel,et al.  ASSOCIATION OF LOW LEVELS OF MANNAN-BINDING PROTEIN WITH A COMMON DEFECT OF OPSONISATION , 1989, The Lancet.

[35]  K. Peuhkurinen.  [Myocardial reperfusion--a double-edged sword?]. , 1989, Duodecim; laaketieteellinen aikakauskirja.

[36]  R. Kloner,et al.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.

[37]  P. Ward,et al.  THE PHLOGISTIC ROLE OF C3 LEUKOTACTIC FRAGMENTS IN MYOCARDIAL INFARCTS OF RATS , 1971, The Journal of experimental medicine.